Komori
Presentation materials for financial results4971MEC COMPANY LTD.Materials and Chemicals

2023年12月期第３四半期決算説明会資料

2023年12月期の通期予想を上方修正し、売上高を300百万円、営業利益を450百万円、経常利益を600百万円、純利益を420百万円引き上げた。一方、第3四半期累計の売上高・営業利益は前年同期を下回っている。

Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
450
¥ million (increase in projected operating profit)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsThird quarter of the fiscal year ended December 202312 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥9,981 million-19.3%
Operating profit¥1,671 million-46.4%
Ordinary income¥1,878 million-45.4%
Net income¥1,707 million-28.4%
Gross Profit Margin59 %
Operating profit margin16.8 %
Selling, general and administrative expenses¥4,214 million
Results for the three months of the current quarter
Net Sales
¥3,782 million
Operating profit
¥833 million
Operating profit margin
22 %
Full-year earnings forecast
Net Sales
¥13,800 million
Operating profit
¥2,250 million
Ordinary income
¥2,500 million
Net income
¥2,150 million
Earnings per share
¥114.07
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales72.3%
Operating profit74.3%
Ordinary income75.1%
Net income79.4%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales密着向上剤、エッチング剤、その他薬品、機械売上、資材売上、その他売上、為替の影響（増減額は図示）
Operating profit薬品売上・数量、薬品粗利益率、機械売上、機械粗利益率、資材およびその他売上、資材およびその他粗利益率、販管費、為替の影響（粗利・販管費）（増減額は図示）
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate
NTD¥4.37
RMB¥19.33
HKD¥16.34
THB¥3.69
EUR¥136.04
USD¥128.03
Foreign exchange sensitivity
NTD
Sales¥42 million
Operating profit¥22 million
RMB
Sales¥15 million
Operating profit¥6 million
New initiatives
新規事業の創出、既存技術の応用展開、電子基板関連分野での事業領域拡大
Key KPIsA metric the company considers important as a management benchmark.
  • 薬品出荷量25,439 t
    Year on year against the same period last year-26.7%
  • EXE sales
    Year on year against the same period last year+0.1%
  • V-Bond sales
    Year on year against the same period last year-7.4%
  • CZ sales
    Year on year against the same period last year-22.8%
  • SF sales
    Year on year against the same period last year-37.6%
  • Overseas revenue ratio62.3 %
Segment results
Regional sales
Japan
  • 1,046
  • 1,376
  • 1,474
Taiwan
  • 615
  • 589
  • 711
China
  • 767
  • 1,081
  • 1,272
Europe
  • 195
  • 240
  • 193
Thailand
  • 140
  • 143
  • 129
Medium-term management plan targets
Consolidated payout ratio30%
ROE2024年10%以上
Financial targets
ROE target2024年10%以上
Number of employees
Number of Employees連結438名、単体253名
Capital expenditures
¥1,763 million
Annual Dividend
Annual¥45.0
Interim¥20.0
End of period¥25.0 per share
Payout ratio
39.4%（2023年12月期予想）、中期目標30%
Acquisition of treasury shares
Total number of shares acquired286,000株
Total acquisition price899,860,700円
Period2023年5月11日〜2023年6月23日
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredThird quarter of the fiscal year ended December 2023
Net Sales¥9,981 million (YoY -19.3%)
Operating profit¥1,671 million (YoY -46.4%)
Ordinary income¥1,878 million (YoY -45.4%)
Net income¥1,707 million (YoY -28.4%)
Gross Profit Margin59 %
Operating profit margin16.8 %
Selling, general and administrative expenses¥4,214 million
Results for the three months of the current quarterNet Sales ¥3,782 million / Operating profit ¥833 million / Operating profit margin 22 %
Full-year earnings forecastNet Sales ¥13,800 million / Operating profit ¥2,250 million / Ordinary income ¥2,500 million / Net income ¥2,150 million / Earnings per share ¥114.07
Progress against full-year forecastNet Sales 72.3% / Operating profit 74.3% / Ordinary income 75.1% / Net income 79.4%
Segment resultsRegional sales Japan 1,046, 1,376, 1,474 / Taiwan 615, 589, 711 / China 767, 1,081, 1,272 / Europe 195, 240, 193 / Thailand 140, 143, 129
Breakdown of Factors Affecting the ChangeNet Sales 密着向上剤、エッチング剤、その他薬品、機械売上、資材売上、その他売上、為替の影響（増減額は図示） / Operating profit 薬品売上・数量、薬品粗利益率、機械売上、機械粗利益率、資材およびその他売上、資材およびその他粗利益率、販管費、為替の影響（粗利・販管費）（増減額は図示）
Key KPIs薬品出荷量 25,439 t, Indicator name EXE sales / value Not disclosed / Year on year against the same period last year 0.1 Year on year, Indicator name V-Bond sales / value Not disclosed / Year on year against the same period last year -7.4 Year on year, Indicator name CZ sales / value Not disclosed / Year on year against the same period last year -22.8 Year on year, Indicator name SF sales / value Not disclosed / Year on year against the same period last year -37.6 Year on year, Overseas revenue ratio 62.3 %
Number of employeesNumber of Employees 連結438名、単体253名 / Change during the period Not disclosed / Hiring plan Not disclosed
Assumptions Underlying the Business OutlookExchange rate NTD ¥4.37 / RMB ¥19.33 / HKD ¥16.34 / THB ¥3.69 / EUR ¥136.04 / USD ¥128.03 / Foreign exchange sensitivity NTD Sales ¥42 million / Operating profit ¥22 million / RMB Sales ¥15 million / Operating profit ¥6 million
Medium-term management plan targetsConsolidated payout ratio 30% / ROE 2024年10%以上
Financial targetsROE target 2024年10%以上 / Actual results Not disclosed
Annual DividendAnnual ¥45.0 / Interim ¥20.0 / End of period ¥25.0 per share
Payout ratio39.4%（2023年12月期予想）、中期目標30%
Acquisition of treasury sharesTotal number of shares acquired 286,000株 / Total acquisition price 899,860,700円 / Period 2023年5月11日〜2023年6月23日
Capital expenditures¥1,763 million
New initiatives新規事業の創出、既存技術の応用展開、電子基板関連分野での事業領域拡大
Items this document does not state (7)
Self-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

通期予想の修正理由は資料中で明示されていない。資料では、短期的には半導体市況の調整や個人消費停滞の影響を見込む一方、中長期的にはPKG基板や関連製品の需要拡大を見込んでいる。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
2023年12月期第３四半期決算説明会資料 | MEC COMPANY LTD. (4971) timely disclosure | Komori